<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941019-2-00078</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The NCI is seeking a pharmaceutical or biotechnology company which, after obtaining a license in accordance with the requirements of the regulations governing the transfer of Government-developed agents (37 CFR part 404), can purify a recombinant CR&hyph;1 protein for which patents are pending or have been issued and to utilize this purified recombinant CR&hyph;1 protein as an immunogen to generate a panel of mouse monoclonal antibodies. The immunoreactive CR&hyph;1 protein has been detected by immunoperoxidase staining using a rabbit anti-peptide polyclonal CR&hyph;1 antibody in a majority of human colon cancers, breast cancers, gastric cancers and pancreatic cancers. Little or no staining was detected in surrounding, noninvolved colon, breast or gastric epithelial cells. In addition, a majority of premalignant colonic adenomas, breast ductal carcinomas  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=3 --> in situ <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  and gastric intestinal metaplasia express immunoreactive CR&hyph;1.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> A recombinant CR&hyph;1 protein has been generated using a yeast expression vector in  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Pichia pastoris  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> and a partially purified protein obtained. This protein as well as synthetic, refolded peptides that correspond to the EGF-like domain in CR&hyph;1 are mitogenic for human breast cancer cells yet fail to bind to the EGF receptor or other type I receptor tyrosine kinases. Expression of CR&hyph;1 antisense mRNA using a recombinant, replication defective retroviral expression vector in colon cancer cells that expresses CR&hyph;1 inhibits the growth of these cells  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> in vivo  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> in nude mice. In order to utilize the diagnostic and therapeutic potentials of CR&hyph;1, it will be necessary to purify a significant amount of the recombinant CR&hyph;1 protein to more fully define its biological properties and to identify the receptor through which it functions. In addition, mouse monoclonal antibodies against the purified CR&hyph;1 recombinant protein will expedite screening studies for CR&hyph;1 expression in other human premalignant lesions and cancers and should exhibit more specificity and sensitivity for the detection of CR&hyph;1 in tissues by immunocytochemistry (ICC) or in tissue extracts or serum samples by ELISA.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> The role of the National Cancer Institute, the Division of Cancer Biology, Diagnosis and Centers includes:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 1. NCI will provide expression vectors that encode CR&hyph;1 and can be used to produce CR&hyph;1 in  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> E. coli. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2. NCI will provide expression vectors that encode CR&hyph;1 in yeast  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Pichia pastoris  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> containing several milligrams of recombinant CR&hyph;1 protein.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3. NCI will provide a rabbit polyclonal anti-CR&hyph;1 antibody for monitoring CR&hyph;1 recovery during the purification from the yeast conditioned medium.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 4. NCI will assay the purified recombinant CR&hyph;1 protein for bioactivity.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 5. NCI will screen anti-CR&hyph;1 monoclonal antibodies for reactivity by Western blot analysis against native CR&hyph;1 protein from CR&hyph;1 positive human embryonal carcinoma or colon carcinoma cells.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <!-- PJG /STAG --></p>
		</main>
</body></html>
            